Acorda therapeutics, inc. (ACOR)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08
Revenues:
Milestone revenue

-

-

-

-

-

-

-

14,376

25,000

-

0

-

Gross product sales

-

-

-

-

-

-

-

-

-

-

-

53,397

Less: discounts and allowances

-

-

-

-

-

-

-

-

-

-

-

5,670

Total net revenues

192,408

471,433

588,287

519,601

492,660

401,480

336,430

305,814

292,237

191,005

54,673

47,826

Grant revenue

-

-

-

-

-

-

-

-

-

-

-

98

Costs and expenses:
Cost of sales

34,849

97,640

111,322

107,475

92,297

79,981

66,009

57,007

64,183

35,518

11,059

11,354

Cost of milestone and license revenue

-

-

634

634

634

634

634

634

2,384

660

330

-

Research and development

60,083

106,383

166,105

203,437

149,209

73,470

53,877

53,881

42,108

30,600

34,611

36,604

Selling, general and administrative

192,846

172,254

181,619

235,437

205,630

201,813

185,545

168,690

148,508

132,657

89,930

73,306

Goodwill and intangible asset impairments

277,561

-

296,763

-

-

-

-

-

-

-

-

-

Amortization of intangible assets

25,636

1,670

23,758

-

-

-

-

-

-

-

-

-

Asset impairment

-

-

-

-

-

6,991

-

664

-

-

-

-

Changes in fair value of acquired contingent consideration

-86,935

55,000

40,900

8,600

10,900

2,200

-

-

-

-

-

-

Total operating expenses

504,040

432,947

821,101

555,583

458,670

365,089

306,065

280,212

257,183

199,435

135,930

121,266

Operating loss

-311,632

38,486

-232,814

-35,982

33,990

36,391

30,365

25,602

35,054

-8,430

-81,257

-73,439

Other (expense) income, net:
Interest and amortization of debt discount expense

21,872

21,597

18,664

16,527

15,472

9,288

2,170

1,880

3,570

3,922

-4,415

5,591

Interest income

4,170

3,518

136

339

440

674

668

552

552

575

1,750

4,682

Other expenses

13

16

-543

9,902

411

232

-

-6

-18

8

-18

8

Gain on debt extinguishment

55,100

-

-

-

-

-

-

-

-

-

-

-

Total other expense, net

37,384

-18,063

-19,071

-6,286

-14,621

-8,382

-1,502

-1,334

-3,036

-3,339

-2,683

-901

Loss before taxes

-274,248

20,423

-251,885

-42,268

19,369

28,009

28,863

24,268

32,018

-11,769

-83,940

-

Benefit from income taxes

-1,282

-13,259

-28,526

-6,665

8,311

10,337

12,422

-130,690

1,413

-

0

-

Net loss

-

-

-

-35,603

11,058

17,672

-

-

-

-

-

-

Net (loss) attributable to non-controlling interest

-

-

-

-985

-

-

-

-

-

-

-

-

Net loss

-272,966

33,682

-223,359

-34,618

11,058

17,672

16,441

154,958

30,605

-11,769

-83,940

-74,340

Net loss per sharebasic and diluted

-

-

-

-

-

-

-

-

-

-

-

-2.19

Weighted average common shares outstanding used in computing net loss per sharebasic and diluted

-

-

-

-

-

-

-

-

-

-

-

33,938

Net loss per share—basic

-5.75

0.72

-4.86

-0.76

0.26

0.43

0.41

3.93

0.78

-0.31

-2.22

-

Net loss per share—diluted

-5.75

0.71

-4.86

-0.76

0.25

0.42

0.39

3.84

0.76

-0.31

-2.22

-

Weighted average common shares outstanding used in computing net loss per share—basic

47,512

47,010

45,999

45,259

42,230

41,150

40,208

39,459

39,000

38,355

37,735

-

Weighted average common shares outstanding used in computing net loss per share—diluted

47,512

47,341

45,999

45,259

43,621

42,544

41,682

40,332

40,064

38,355

37,735

-

Net Product Revenues
Total net revenues

180,736

459,739

549,749

493,358

466,111

373,292

310,317

282,381

256,271

181,545

49,959

47,727

Royalty Revenues
Total net revenues

11,672

11,694

29,481

17,186

17,492

19,131

17,056

-

1,909

32

0

-

License Revenue
Total net revenues

-

-

9,057

9,057

9,057

9,057

9,057

9,057

9,057

9,428

4,714

0